Current Updates
RXR Agonists

Connexios presented data on therapeutic action of CNX-013-B2 at the Diabetes and Metabolic Dysfunction (J6) - Keystone Symposia, Jan 2015

Current Updates
T2DM Metabolomics

T2DM Metabolomics article published in Molecular BioSystems, Nov 2014

Current Updates
ADA 2014

Connexios presented new data on CNX-013-B2, a pan-PPAR RXR agonist at ADA's 74th Scientific Sessions

Current Updates
AMPK Activators

Connexios Life Sciences and Boehringer Ingelheim Enter Agreement for Novel AMPK Activators

Click

About us

News & Events

Next GENERATION therapies

About Us

Connexios is a venture-backed company established in 2003. We are building a broad innovative clinical pipeline that aims to address the critical clinical gaps in Type 2 Diabetes and related metabolic diseases. Our expertise in the metabolic diseases space is based on our proprietary Network Biology platform that enables us to link the cellular and molecular events and processes.

more

News & Events

  • 29 JAN Therapeutic action of CNX-013-B2: similarity and synergy with exercise training in C57BL6/j mice on high fat diet
  • 25 NOV Investigating correlations in the altered metabolic profiles of obese and diabetic subjects in a South Indian Asian population using an NMR-based metabolomic approach
more

Next Generation Therapies

We beleive that effective therapies have to engage with dysregulations in cell function and outcomes across different tissues in order to provide a robust therapeutic impact.

This is practically true in case of chronic, systemic and multifactorial diseases like T2D.

more